IBEC spin-off Nanobots Therapeutics has been selected in the AECC’s 2024 call for IMPACTO grants. This is an initiative of the Spanish Association Against Cancer (AECC) aimed at technology-based micro-enterprises and SMEs to accelerate the arrival of new treatments in the clinic. The grants were awarded in Barcelona today.
IBEC spin-off Nanobots Therapeutics is one of the companies selected in the AECC IMPACTO 2024 call, an initiative of the Spanish Association Against Cancer (AECC) to promote the development of innovative technology-based companies to provide biomedical solutions for cancer patients. The grant was awarded to Samuel Sánchez, IBEC Principal Investigator and academic founder of the company, and Marta Soler, Operations Director of Nanobots Therapeutics.
Founded in 2023 as a spin-off from IBEC and ICREA, Nanobots Therapeutics is developing an innovative technology platform called MotionTx, based on nanorobots capable of crossing biological barriers and delivering drugs to diseased cells. This technology represents a disruptive approach to drug delivery with the aim of improving the efficacy of cancer treatments and reducing their side effects.
The AECC IMPACTO call is aimed at technology-based micro-enterprises and SMEs that are less than five years old and are focused on the development and commercialisation of innovative biomedical solutions. Through a participatory loan, this programme aims to accelerate the arrival of new treatments and therapies in clinical practice, facilitating their application to cancer patients.
The award ceremony took place today, 24 February, at the Auditori MGS in Barcelona, during an event that brought together researchers and entrepreneurs from the biomedical sector. For Nanobots Therapeutics, this funding is an important step towards the preclinical validation and future application of its technology in the treatment of cancer, consolidating its role as a leader in the field of therapeutic nanorobotics.
